Joint (NASDAQ:JYNT) Stock Crosses Above 50-Day Moving Average – Should You Sell?

The Joint Corp. (NASDAQ:JYNT) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $8.85 and traded as high as $9.52. Joint shares last traded at $9.21, with a volume of 227,241 shares.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on JYNT. Wall Street Zen downgraded Joint from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Weiss Ratings upgraded Joint from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, June 12th. Finally, Zacks Research raised Joint from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Joint Stock Down 7.5%

The firm has a market cap of $121.50 million, a price-to-earnings ratio of 37.04 and a beta of 1.12. The business’s fifty day moving average is $8.84 and its two-hundred day moving average is $8.95.

Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.05. The firm had revenue of $14.82 million for the quarter, compared to the consensus estimate of $14.50 million. Joint had a return on equity of 7.00% and a net margin of 5.72%. Research analysts forecast that The Joint Corp. will post 0.51 EPS for the current year.

Insider Activity

In other news, major shareholder Charles E. Jobson purchased 127,676 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were acquired at an average price of $8.57 per share, with a total value of $1,094,183.32. Following the completion of the purchase, the insider directly owned 1,773,479 shares of the company’s stock, valued at $15,198,715.03. The trade was a 7.76% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 30.20% of the stock is owned by company insiders.

Institutional Trading of Joint

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its stake in shares of Joint by 1.8% in the 4th quarter. Deutsche Bank AG now owns 84,745 shares of the company’s stock valued at $739,000 after purchasing an additional 1,462 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Joint by 104.7% during the third quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company’s stock worth $28,000 after buying an additional 1,501 shares during the last quarter. Barclays PLC raised its stake in shares of Joint by 5.3% during the fourth quarter. Barclays PLC now owns 32,235 shares of the company’s stock worth $281,000 after buying an additional 1,623 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Joint by 25.9% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock valued at $95,000 after buying an additional 1,698 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Joint by 32.3% in the second quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock valued at $86,000 after buying an additional 1,810 shares during the period. 76.88% of the stock is owned by institutional investors.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.